TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: CD133(+)/VEGFR‐2(+) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial cell-forming clusters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unscheduled follow-up visits for acute diarrhea
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reduction in sleep disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Communication skills improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Global competency achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 10-year FFSR
Endpoint domain: Mortality/survival
Primary endpoint: 10-year OS
Endpoint domain: Mortality/survival
Primary endpoint: Total QRS count per 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma and urinary norepinephrine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: 5-km time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prospective memory (PM) task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mac‐1 surface expression on monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GP Ib alpha fluorescence intensity of heterotypic aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial VLDL-apoB-100 total area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting plasma apoB-48 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial triglyceride total area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: visual benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: foveal optical coherence tomographic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: task-completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean postprandial blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of employment problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Simulated area under the magnesium serum concentration‐time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores with movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% human infectious dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery to normospermic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Self-efficacy in managing RTI patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resorption rate of alveolar bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: general patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of IEE classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean duration of axillary drainage placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of seroma aspirations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Volume of intraperitoneal drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVAD flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in epicardial adipose tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in pericardial adipose tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean reduction in daily sitting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute respiratory failure requiring noninvasive ventilation or intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects requiring new or increased immunosuppressive treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Flares of Systemic Lupus Erythematosus Disease Activity Index
Endpoint domain: Adverse events/effects
Primary endpoint: Number of active caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean deviation of visual fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pattern standard deviation of visual fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: short-term fluctuation of visual fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FPR-BS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FPS-CS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean nodule volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NSAID usage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: positive blood cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean height/width ratio of the anteromedial femoral tunnels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean aperture axis angle of the posterolateral femoral tunnels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean position of the posterolateral femoral tunnels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of dependence on substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of suicidal thinking
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients not wearing spectacles or contact lenses for distance vision
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean refractive error at 10 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of spectacle-corrected visual acuity of 2 lines or more
Endpoint domain: Adverse events/effects
Primary endpoint: HbA1c reduction from baseline to week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants achieving HbA1c target of <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Freezing of gait performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroop test performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: percentage of patients reaching a clinically relevant enhancement of HrQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reaction times of saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: error rates in the antisaccade condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean daily adherence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major strokes
Endpoint domain: Mortality/survival
Primary endpoint: Central SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severity of ocular surface conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of incident Alzheimer's disease (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days with symptoms and/or drug intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term interest in health-related research
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heart rate of 60 beats per minute or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically significant improvement in depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RFA measurements and marginal bone level correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RFA and PISF volume correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death, seizures, and coma
Endpoint domain: Mortality/survival
Primary endpoint: Blood Glucose Level (BGL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of echolucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of echodensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: demineralized enamel area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper-extremity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower-extremity performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dexterity of the less affected upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: static standing balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper and lower extremity muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean topographic astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of serum TSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentrations of fT3 and fT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Concentrations of sFas and sFasL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Labor pain sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual acuity maintenance or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central subfield thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-VEGF injection requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participation in work and school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Inhibition of THC-induced body sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of THC-induced heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary inflammatory response attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duloxetine continuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PGI‐I ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IEF reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: length of small bowel visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neurological deficits
Endpoint domain: Mortality/survival
Primary endpoint: Total Z test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 30-day mortality and major morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Confidence in managing hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in perfusion in injected areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uncomplicated postoperative course
Endpoint domain: Adverse events/effects
Primary endpoint: Composite end point of death or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Urinary aldosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: periprocedural stroke and death (S+D)
Endpoint domain: Mortality/survival
Primary endpoint: S+D at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: primary end point
Endpoint domain: Mortality/survival
Primary endpoint: Cough disappearance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first mechanical-catheter failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical effects improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade III/IV nausea, vomiting, and loss of appetite
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Spasm free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF p-tau concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain amyloid burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: balance impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: naming accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchoprotective effect against exercise-induced asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postdischarge NM-PO
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma IL-22 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Th1 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of Th22 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perceived importance of nutrition when eating out
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fat-free mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fat mass decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QoL-AGHDA score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Reach (FR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from EII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from EII-related reintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aneurysm sac volume shrinkage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARI days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe ARI days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate to severe sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Irregularities in the coronal zone of the hybrid layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of cariogenic bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1c (A1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retrograde colonic spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma concentrations of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of ropivacaine
Endpoint domain: Adverse events/effects
Primary endpoint: Mean BDI score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in inspiratory muscle strength (%PImax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in expiratory muscle strength (%PEmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in respiratory complications
Endpoint domain: Adverse events/effects
Primary endpoint: recurrent primary endpoint events
Endpoint domain: Mortality/survival
Primary endpoint: CV death following non-fatal event
Endpoint domain: Mortality/survival
Primary endpoint: total primary efficacy events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: macrophage volume fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: granuloma volume fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: endothelial cell volume fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Elevated umbilical venous cord blood plasma IL-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBS increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cost savings per woman
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in Vancouver Scar Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: FIB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: stool form score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: colon volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean annual rates of GVF change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic equivalence of LB80380 maleate and LB80380 free base tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with induction process
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: myocardial blood flow estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Facial pain scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery to spontaneous respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Composite YBT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in BMD at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in BMD at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in serum heat-labile alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sales of sugar-sweetened beverages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of full digital block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Viability of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes